Product Description
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucoselevels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucoselevels without hypoglycemic effects. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bisegliptin)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: ActivX Biosciences, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes|General Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2009-015071-27 |
Synergy 104 | P2 |
Completed |
Type 2 Diabetes |
2011-01-19 |
2022-03-13 |
Treatments |
|
NCT00995345 |
Synergy104 | P2 |
Completed |
Type 2 Diabetes |
2011-01-01 |
2019-03-19 |
Treatments |
|
NCT00525330 |
NCT00525330 | P2 |
Completed |
Type 2 Diabetes |
2008-08-01 |
2019-03-21 |
Treatments |
|
JapicCTI-090735 |
JapicCTI-090735 | P2 |
Completed |
General Diabetes |
None |
Recent News Events
Date |
Type |
Title |
|---|